Skip to Content

Coronavirus information for Feinberg.

Download the full-sized PDF of Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury
Download the file

Actions

Download Analytics Citations

Export to: EndNote

Collections

This file is in the following collections:

COVID-19 Community

Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury Open Access (recommended)

Jin H, Zhao ZG, Lan Q, Zhou HT, Mai ZS, Wang Y, Ding XW, Zhang WT, Pi J, Evans CE, Liu XG. Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury. Frontiers in Pharmacology. 2021;11:10.

Descriptions

Resource type(s)
Article
Keyword
cytokine storm syndrome
hesperidin
chitosan nanoparticle
lung inflammation
nasal drug delivery
Rights
Attribution 4.0 International

Creator
Jin, Hua
Zhao, Zuguo
Lan, Qian
Zhou, Haotong
Mai, Zesen
Wang, Yuan
Ding, Xiaowen
Zhang, Wenting
Pi, Jiang
Evans, Colin Edward
Liu, Xinguang
Abstract
The cytokine storm or cytokine storm syndrome (CSS) is associated with high mortality in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), for example following sepsis or infectious diseases including COVID-19. However, there are no effective treatments for CSS-associated ALI or ALI/ARDS. Thus, there remains an urgent need to develop effective drugs and therapeutic strategies against CSS and ALI/ARDS. Nasal and inhaled drug delivery methods represent a promising strategy in the treatment of inflammatory lung disease as a result of their ability to improve drug delivery to lungs. Improving the nasal mucosa absorption of poorly water-soluble drugs with poor mucosa bioavailability to a therapeutically effective level is another promising strategy in the fight against ALI/ARDS. Here, chitosan nanoparticles loaded with hesperidin (HPD/NPs) were developed for nasal delivery of the anti-inflammatory HPD compound to inflammatory lungs. In vitro and in vivo, HPD/NPs exhibited enhanced cellular uptake in the inflammatory microenvironment compared with free HPD. In a mouse model of inflammatory lung disease, the HPD/NPs markedly inhibited lung injury as evidenced by reduced inflammatory cytokine levels and suppressed vascular permeability compared with free HPD. Collectively, our study demonstrates that nasal delivery of HPD/NPs suppresses CSS and ALI/ARDS in a murine model of inflammatory lung disease, and that nanoparticle-based treatment strategies with anti-inflammatory effects could be used to reduce CSS and ALI in patients with inflammatory lung injury.
Related URL
Publisher
FRONTIERS MEDIA SA
Date Created
2021-01-27
Original Identifier
(PMID) 33584267
Grants and funding
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81971329, 81671399]; Special Funds for the Cultivation of Guangdong College Students'Scientific, Technological Innovation (Climbing Program Special Funds) [pdjh2019b0224]; PhD early development program of Guangdong medical University [B2019012]; Group-type Special Supporting Project for Educational Talents in Universities [4SG19057G]; American Heart Association Career Development AwardAmerican Heart Association [19CDA34500000]
DOI
10.3389/fphar.2020.592238

File Details

File Properties
Mime type: application/pdf
File size: 3415.2 kB